Arecor Therapeutics (AREC.L) Stock Price
£63.5 0%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
1 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Arecor Therapeutics, AI stock picks, stock alerts and much more.
AREC.L AI Stock Analysis
AI stock analysis for AREC.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Arecor Therapeutics (AREC.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Arecor Therapeutics (AREC.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Arecor Therapeutics (AREC.L), currently trading at £63.5, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About AREC.L
-
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications.
-
Symbol
AREC.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
24M
Similar Stocks
 |
Codexis 0I0X.L |
$3 5.5% |
5 |
 |
Oxford Nanopore Technologies plc ONT.L |
£208.2 1.3% |
7 |
 |
Sareum Holdings SAR.L |
£22 8.3% |
5 |
 |
Viridian Therapeutics 0K1R.L |
$19.19 8.5% |
6 |
 |
Avacta Group Plc AVCT.L |
£49 1% |
4 |
News
AREC.L Alternative Data
Web Traffic
Arecor Therapeutics receives an estimated 3300 monthly visitors to arecor.com.
-
Web Traffic
3300
-
Change from Previous Month
17.4%
-
3 Month Change
5%
-
YoY Change
5%
Twitter Followers
Arecor Therapeutics has 341 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
341
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.6%
-
YoY Change
0.6%
Facebook Engagement
Arecor Therapeutics has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Job Postings
Arecor Therapeutics currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Followers
3,619 are following Arecor Therapeutics on LinkedIn, up by 1.6% over the last month.
-
LinkedIn Followers
3619
-
Daily Change
1.6%
-
1 Month Change
1.6%
-
3 Month Change
4.2%
-
YoY Change
4.2%
LinkedIn Employees
According to LinkedIn, Arecor Therapeutics has 34 employees.
-
LinkedIn Employees
34
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
6.3%
-
YoY Change
6.3%
Business Outlook
According to employee reviews, the business outlook among employees at Arecor Therapeutics is 83 out of 100 (very bullish).
-
Business Outlook
83
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
News Mentions
Arecor Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
Arecor Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
1 Month Change
0%
-
3 Month Change
0%
AREC.L Financials
AREC.L Key Metrics
-
Total Revenue
£3.1M
-
Net Income
-£5.6M
-
Earnings per Share
-£0.15
-
Free cash flow
-£5M
-
EBITDA
-£5.6M
-
EBITDA Ratio
-1.83028
-
Total Assets
£8.7M
AREC.L 2-year Revenue & Income
AREC.L 2-year Free Cash Flow
AREC.L Technicals
AREC.L SMA
AREC.L RSI
FAQ
What's the current price of Arecor Therapeutics (AREC.L) Stock?
The price of an Arecor Therapeutics (AREC.L) share is £63.5.
What's the market cap of Arecor Therapeutics?
The current market cap of Arecor Therapeutics is 24M.
Should I buy or sell AREC.L?
Arecor Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Arecor Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is Arecor Therapeutics a good investment?
The current analysis of Arecor Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Arecor Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Arecor Therapeutics (AREC.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Arecor Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Arecor Therapeutics (AREC.L) that investors often compare it to?
Arecor Therapeutics (AREC.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for Arecor Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Arecor Therapeutics' stock price to be around £65.86 in 2026. Starting from the current price of £63.5, this represents a 3.7% change in price, indicating a neutral outlook for the stock.
How to buy Arecor Therapeutics (AREC.L) Stock?
Arecor Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Arecor Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.